Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on gene circuit engineering for oncology applications. The company became publicly traded in June 2022 through a business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS), a blank-check company sponsored by Dynamics Special Purpose Holdings LLC. Senti operates in the biotechnology sector, with its lead programs targeting hematologic malignancies using programmable cell therapies. The company filed an 8-K current report with the SEC on September 4, 2026, accession number 0001628280-26-060600. For full filing details, ownership data, and real-time SPAC analytics on SNTI and hundreds of other de-SPAC companies, sign up for SpacDesk at spacdesk.com.